⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1102254 | 0.84 | — | — | |
| SCHEMBL840809 | 0.78 | — | — | |
| SCHEMBL17675550 | 0.75 | — | — | |
| SCHEMBL737186 | 0.74 | — | — | |
| SCHEMBL10212049 | 0.73 | — | — | |
| SCHEMBL839921 | 0.73 | — | — | |
| SCHEMBL840154 | 0.72 | — | — | |
| SCHEMBL10975460 | 0.72 | — | — | |
| SCHEMBL10226247 | 0.70 | — | — | |
| SCHEMBL840069 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239811-A1 | 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE T | REMIX THERAPEUTICS INC. | 2024-07-18 | — | — | US | disclosed |
| US-20230365526-A1 | PYRIDAZINE DERIVATIVES FOR MODULATING NUCLEIC ACID SPLICING | REMIX THERAPEUTICS INC (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230365566-A1 | HETEROCYCLIC AMIDES AND THEIR USE FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2023150394-A1 | METHODS FOR TREATMENT OF CANCER | FRONTIER MEDICINES CORPORATION (US) | 2023-08-10 | — | — | WO | disclosed |
| US-11718641-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718641-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230167093-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230159496-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230140983-A1 | PYRIDAZINE DERIVATIVES FOR MODULATING NUCLEIC ACID SPLICING | REMIX THERAPEUTICS INC (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230148184-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| US-20080119453-A1 | Bicyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2008-05-22 | — | — | US | disclosed |
| US-20080113990-A1 | Biphenyl derivatives as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2008-05-15 | — | — | US | disclosed |
| US-20080027067-A1 | Heterocyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-31 | — | — | US | disclosed |
| US-20070276001-A1 | Biphenyl-pyrazolecarboxamide compounds | CONCERT PHARMACEUTICALS INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070203130-A1 | Bicyclic derivatives as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-30 | — | — | US | disclosed |
| US-20070203130-A1 | Bicyclic derivatives as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-30 | — | — | US | disclosed |
| US-20070117801-A1 | Indane derivatives as modulator of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-05-24 | — | — | US | disclosed |
| WO-2007033366-A2 | BIPHENYL-PYRAZOLECARBOXAMIDE COMPOUNDS | CONCERT PHARMACEUTICALS INC. (US) | 2007-03-22 | — | — | WO | disclosed |
| US-20070066657-A1 | obesity, smoking cessation, and normalization of blood lipid composition; reduced rates of hepatic oxidative metabolism, ability to penetrate the blood-brain barrier; 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(trideuteromethyl)-1H-pyrazole-3-carboxylic acid; cannabinoid receptor antagonist | CONCERT PHARMACEUTICALS INC. (US) | 2007-03-22 | — | — | US | disclosed |
| US-20060025415-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2006-02-02 | — | — | US | disclosed |